FDA Investigator Xu Michael Di, PhD

Xu Michael Di, PhD has conducted inspections on 3 sites in 2 countries as of 03 May 2023. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
3
Last Inspection Date:
03 May 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
100002587
Countries of Inspections:
United States of America, Ireland
FDA Investigators that have inspected at least one site in common with Xu Michael Di, PhD:
Aimee Cunningham, PhD, Alicia M Mozzachio, Anastasia M Shields, Andrew J Barrowcliff, Arie C Menachem, Arulvathani P Arudchandran, Bijoy Panicker, Bo Chi, PhD, Brooke K Higgins, Carl A Huffman, III, CDR Donald Ertel, Concepcion Cruz, Jr, Cynthia Jim, CSO, Dennis Cantellops Paite, Diane L Raccasi, Dianne S Alexander, Dr. Ralph M Bernstein, PhD, Dr. Zhihao Qiu (Peter), PhD, Emest F Bizjak, Erin D Mccaffery, Erin L Mcfiren, Francis A Guidry, Hailin Wang (Sheena), PhD, Haoheng Yan, PhD, Howard Anderson, PhD, Jacqueline Mdiaz Albertini, Javier E Santos, Jennifer Swisher, PhD, Jing Fang, John F Cipollo, Jonathan W Chapman, Junho Pak, Kalavati Suvarna, PhD, Kelly R Lewis, Kshitij A Patkar, Lakshmi Narasimhan, PhD, Laura Fontan, MS, Li Lu, PhD, Linda Thai, Madushini Dharmasena, PhD, Maria Cecilia Tami, PhD, Maria Gutierrez Hoffman, PhD, Maria Joselopez Barragan, PhD, Michael Shanks, MS, Michele L Obert, Mihaly S Ligmond, Milos Dokmanovic, PhD, Mra Davism, Nancy T Waites, Nebil A Oumer, Omotunde O Osunsanmi, Patrick C Klotzbuecher, Paula A Trost, Prabhu P Raju, Qin Xu, Richard Ledwidge (nmi), PhD, Richard W Thornton, Rose Ashley, Scott E Norris, Sena G Dissmeyer, Shirley J Berryman, Steven Kozlowski, MD, Steven P Donald, Susan M Jackson, Tina S Roecklein, Viviana Matta, Wayne E Seifert, Yasamin Ameri, Yun Wu, PhD, Zhao Wang, PhD, Zhong Li, PhD

Xu Michael Di, PhD's Documents

Publish Date Document Type Title
January, 2017 FDA 483 AstraZeneca Pharmaceuticals LP - Form 483, 2017-01-27
June, 2015 FDA 483 Eli Lilly Kinsale Limited - Form 483, 2015-06-26
May, 2023 FDA 483 Pfizer Ireland Pharmaceuticals - Form 483, 2023-05-11

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more